These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3539961)

  • 1. Standardized methods of causality assessment for suspected adverse drug reactions.
    Hutchinson TA; Lane DA
    J Chronic Dis; 1986; 39(11):857-60. PubMed ID: 3539961
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse effect reporting: pharmaceutical companies can't be trusted.
    Prescrire Int; 2015 Nov; 24(165):256. PubMed ID: 26688890
    [No Abstract]   [Full Text] [Related]  

  • 3. Adverse drug reactions.
    Lawson DH
    Hum Toxicol; 1985 Mar; 4(2):122-6. PubMed ID: 4007876
    [No Abstract]   [Full Text] [Related]  

  • 4. Post-marketing surveillance of adverse reactions to new medicines.
    Wilson AB
    Br Med J; 1977 Oct; 2(6093):1001-3. PubMed ID: 922357
    [No Abstract]   [Full Text] [Related]  

  • 5. What do stakeholders think about pharmacovigilance?
    Edwards IR; Graedon T
    Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819
    [No Abstract]   [Full Text] [Related]  

  • 6. Risky business.
    Nat Med; 2009 Apr; 15(4):345. PubMed ID: 19349989
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmaceutical drugs-the good and the not so good: together, we can make it better.
    Campbell AW
    Altern Ther Health Med; 2014; 20(1):9-11. PubMed ID: 24445351
    [No Abstract]   [Full Text] [Related]  

  • 8. Patents and the quality, safety and efficacy of medicines.
    du Toit K; du Preez W; Padayachee S
    S Afr Med J; 2015 Nov; 105(11):905-6. PubMed ID: 26632315
    [No Abstract]   [Full Text] [Related]  

  • 9. Vital roles for the pharmacist.
    Kennedy EM
    J Am Pharm Assoc; 1973 Oct; 13(10):562-3. PubMed ID: 4750415
    [No Abstract]   [Full Text] [Related]  

  • 10. Proceedings of the symposium on safety pharmacology, presented during the 3rd EPHAR meeting, Lyon, 6-9 July 2001. European Pharmacological Societies.
    Fundam Clin Pharmacol; 2002 Apr; 16(2):73-156. PubMed ID: 12102033
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA tells drug and device makers to give balanced picture of risks in ads, labels.
    Kuehn BM
    JAMA; 2009 Jun; 301(24):2541. PubMed ID: 19549965
    [No Abstract]   [Full Text] [Related]  

  • 12. 2nd Annual Conference on Cardiac Safety of New Drug Products: Philadelphia, PA, USA, March 24-25, 2003.
    Scriabine A
    Cardiovasc Drug Rev; 2003; 21(3):236-41. PubMed ID: 14582479
    [No Abstract]   [Full Text] [Related]  

  • 13. Initial development and testing of an instrument for patient self-assessment of adverse drug reactions.
    Jarernsiripornkul N; Chaipichit N; Pratipanawatr T; Uchaipichat V; Krska J
    Pharmacoepidemiol Drug Saf; 2016 Jan; 25(1):54-63. PubMed ID: 26349635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Innovation and therapeutic progress].
    Revuz J
    Ann Dermatol Venereol; 2006 Feb; 133(2):111-2. PubMed ID: 16508592
    [No Abstract]   [Full Text] [Related]  

  • 15. Adverse drug reactions: physicians' opinions versus a causality assessment method.
    Miremont G; Haramburu F; Bégaud B; Péré JC; Dangoumau J
    Eur J Clin Pharmacol; 1994; 46(4):285-9. PubMed ID: 7957509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Delivery to the Lungs (DDL)--18th conference.
    Seville P
    IDrugs; 2008 Mar; 11(3):161-3. PubMed ID: 18311647
    [No Abstract]   [Full Text] [Related]  

  • 17. Post-marketing surveillance in the UK (1984).
    Lawson DH
    Br J Clin Pharmacol; 1986; 22 Suppl 1(Suppl 1):71S-75S. PubMed ID: 3567035
    [No Abstract]   [Full Text] [Related]  

  • 18. Commentary: how the doctor can counter commercial bias in the dissemination of pharmacotherapeutic knowledge.
    Carpenter WT
    J Nerv Ment Dis; 2002 Sep; 190(9):593-6. PubMed ID: 12357092
    [No Abstract]   [Full Text] [Related]  

  • 19. [Unification of standard industrial regulations regarding free distribution of the devices for individual protection].
    Khodakova VN
    Antibiot Khimioter; 1991 Dec; 36(12):21-2. PubMed ID: 1839948
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury.
    García-Cortés M; Lucena MI; Pachkoria K; Borraz Y; Hidalgo R; Andrade RJ;
    Aliment Pharmacol Ther; 2008 May; 27(9):780-9. PubMed ID: 18284654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.